[Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation].
Vinogradova Oa, Zakharova Av, Savchenko Vg(National Research Center for Hematology Russian Academy of Medical Sciences), Diachenko Lv, Liubimova Ls, Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Domracheva Ev, Е. Н. Паровичникова(National Research Center for Hematology Russian Academy of Medical Sciences)
PubMed
January 1, 2002
Cited by 1
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59